Clinical Diabetes: a Publication of the American Diabetes Association, 38 (4), 390402
These early insights from the COURAGE trialclearly establish the principle that blocking GDF8 with or without activin A can preserve muscle and further increase fat loss in patients being treated with GLP-1 therapy, thereby improving the quality of weight loss, said George Yancopoulos, president and chief scientific officer at Regeneron, in a statement from the company
Thus, the additional activity observed after reduction with DTT cannot be explained by the presence of oxidized GST in the samples
This indicates that there are mechanisms that go well beyond just weight loss or glucose lowering, she says
Ecnoglutide, which Pfizer licensed from Sciwind Biosciences, is already approved in China for type 2 diabetes mellitus, and a marketing application for weight loss has been accepted by regulatory authorities in the country
Its regulatory status has not halted demand either